Enterobacter aerogenes ZDY01 Attenuates Choline-Induced Trimethylamine N-Oxide Levels by Remodeling Gut Microbiota in Mice
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Trimethylamine N-oxide (TMAO), which is transformed from trimethylamine (TMA) through hepatic flavin-containing monooxygenases, can promote atherosclerosis. TMA is produced from dietary carnitine, phosphatidylcholine, and choline via the gut microbes. Previous works have shown that some small molecules, such as allicin, resveratrol, and 3,3-dimethyl-1- butanol, are used to reduce circulating TMAO levels. However, the use of bacteria as an effective therapy to reduce TMAO levels has not been reported. In the present study, 82 isolates were screened from healthy Chinese fecal samples on a basal salt medium supplemented with TMA as the sole carbon source. The isolates belonged to the family Enterobacteriaceae, particularly to genera Klebsiella, Escherichia, Cronobacter, and Enterobacter. Serum TMAO and cecal TMA levels were significantly decreased in choline-fed mice treated with Enterobacter aerogenes ZDY01 compared with those in choline-fed mice treated with phosphate-buffered saline. The proportions of Bacteroidales family S24-7 were significantly increased, whereas the proportions of Helicobacteraceae and Prevotellaceae were significantly decreased through the administration of E. aerogenes ZDY01. Results indicated that the use of probiotics to act directly on the TMA in the gut might be an alternative approach to reduce serum TMAO levels and to prevent the development of atherosclerosis and “fish odor syndrome” through the effect of TMA on the gut microbiota.
Abstract
Trimethylamine N-oxide (TMAO), which is transformed from trimethylamine (TMA) through hepatic flavin-containing monooxygenases, can promote atherosclerosis. TMA is produced from dietary carnitine, phosphatidylcholine, and choline via the gut microbes. Previous works have shown that some small molecules, such as allicin, resveratrol, and 3,3-dimethyl-1- butanol, are used to reduce circulating TMAO levels. However, the use of bacteria as an effective therapy to reduce TMAO levels has not been reported. In the present study, 82 isolates were screened from healthy Chinese fecal samples on a basal salt medium supplemented with TMA as the sole carbon source. The isolates belonged to the family Enterobacteriaceae, particularly to genera Klebsiella, Escherichia, Cronobacter, and Enterobacter. Serum TMAO and cecal TMA levels were significantly decreased in choline-fed mice treated with Enterobacter aerogenes ZDY01 compared with those in choline-fed mice treated with phosphate-buffered saline. The proportions of Bacteroidales family S24-7 were significantly increased, whereas the proportions of Helicobacteraceae and Prevotellaceae were significantly decreased through the administration of E. aerogenes ZDY01. Results indicated that the use of probiotics to act directly on the TMA in the gut might be an alternative approach to reduce serum TMAO levels and to prevent the development of atherosclerosis and “fish odor syndrome” through the effect of TMA on the gut microbiota.
참고문헌 (36)
- Sekirov I, "Gut microbiota in health and disease", Physiol. Rev, 90, pp.859~904 (2010)
- Lee WJ, "Gut microbiota-generated metabolites in animal health and disease", Nat. Chem. Biol, 10, pp.416~424 (2014)
- Tremaroli V, "Functional interactions between the gut microbiota and host metabolism", Nature, 489, pp.242~249 (2012)
- Bennett BJ, "Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation", Cell Metab, 17, pp.49~60 (2013)
- Wang Z, "Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease", Nature, 472, pp.57~65 (2011)
- Koeth RA, "Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis", Nat. Med, 19, pp.576~585 (2013)
- Tang WHW, "Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk", N. Engl. J. Med, 368, pp.1575~1584 (2013)
- Ulman CA, "Fish odor syndrome: a case report of trimethylaminuria", Dermatol. Online J, 20, pp.21260~ (2014)
- Brugere JF, "Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease", Gut Microbes, 5, pp.5~10 (2014)
- Kuka J, "Suppression of intestinal microbiotadependent production of pro-atherogenic trimethylamine Noxide by shifting L-carnitine microbial degradation", Life Sci, 117, pp.84~92 (2014)
- Wu W-K, "Dietary allicin reduces transformation of L-carnitine to TMAO through impact on gut microbiota", J. Funct. Foods, 15, pp.408~417 (2015)
- Wang Z, "Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis", Cell, 163, pp.1585~1595 (2015)
- Chen ML, "Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota", mBio, 7, pp.e02210~e02215 (2016)
- Miao J, "Flavin-containing monooxygenase 3as a potential player in diabetes-associated atherosclerosis", Nat. Commun, 6, pp.6498~ (2015)
- Shih DM, "Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis", J. Lipid Res, 56, pp.22~37 (2015)
- Gregory JC, "Transmission of atherosclerosis susceptibility with gut microbial transplantation", J. Biol. Chem, 290, pp.5647~5660 (2015)
- Mejean V, "TMAO anaerobic respiration in Escherichia coli: involvement of the tor operon", Mol. Microbiol, 11, pp.1169~1179 (1994)
- Ocque AJ, "Development and validation of a simple UHPLC-MS", MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine, 2015, pp.109, 128~135
- Romano KA, "Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide", mBio, 6, pp.e02481~ (2015)
- Magoc T, "FLASH: fast length adjustment of short reads to improve genome assemblies", Bioinformatics, 27, pp.2957~2963 (2011)
- Bokulich NA, "Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing", Nat. Methods, 10, pp.57~59 (2013)
- Edgar RC, "UPARSE: highly accurate O TU s equences from microbial amplicon reads", Nat. Methods, 10, pp.996~998 (2013)
- Wang Q, "Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy", Appl. Environ. Microbiol, 73, pp.5261~5267 (2007)
- Suchodolski JS, "The fecal microbiome in cats with diarrhea", PLoS One, 10, pp.e0127378~ (2015)
- Randrianarisoa E, "Relationship of serum trimethylamine N-oxide (TMAO) levels with early atherosclerosis in humans", Sci. Rep, 6, pp.26745~ (2016)
- Kim SG, "Isolation and characterization of novel halotolerant and", or halophilic denitrifying bacteria with versatile metabolic pathways for the degradation of trimethylamine, 2003, pp.225, 263~269
- Mewies M, "Flavinylation in wild-type trimethylamine dehydrogenase and differentially charged mutant enzymes: a study of the protein environment around the N1 of the flavin isoalloxazine", Biochem. J, 317, pp.267~272 (1996)
- Liffourrena AS, "Identification, cloning and biochemical characterization of Pseudomonas putida A (ATCC 12633) monooxygenase enzyme necessary for the metabolism of tetradecyltrimethylammonium bromide", Appl. Biochem. Biotechnol, 173, pp.552~561 (2014)
- Kasprzak AA, "Identity of the subunits and the stoichiometry of prosthetic groups in trimethylamine dehydrogenase and dimethylamine dehydrogenase", Biochem. J, 211, pp.535~541 (1983)
- Koeth RA, "γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO", Cell Metab, 20, pp.799~812 (2014)
- Denby KJ, "Adaptation of anaerobic cultures of Escherichia coli K-12 in response to environmental trimethylamine-Noxide", Environ. Microbiol, 17, pp.2477~2491 (2015)
- Hoyles L, "Reduction of trimethylamine N-oxide to trimethylamine by the human gut microbiota: supporting evidence for ‘metabolic retroversion’", Poster in Conference on Exploring Human Host-Microbiome Interactions in Health and Disease (2015)
- Chen Y, "Bacterial flavin-containing monooxygenase is trimethylamine monooxygenase", Proc. Natl. Acad. Sci. USA, 108, pp.17791~17796 (2011)
- Ussher JR, "Gut microbiota metabolism of L-carnitine and cardiovascular risk", Atherosclerosis, 231, pp.456~461 (2013)
- Moller B, "Degradation of various amine compounds by mesophilic clostridia", Arch. Microbiol, 145, pp.85~90 (1986)
- Zhu Y, "Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota", Proc. Natl. Acad. Sci. USA, 111, pp.4268~4273 (2014)